Morgan Stanley estimates that AI-related investment’s contribution to U.S. GDP growth has risen from 0.2 percentage points in 2024 to 0.9 percentage points so far in 2026; productivity gains are concentrated mainly in AI-exposed industries, while permitting, power-supply and oil-price shocks could slow investment and its pass-through to growth.
Existing-home transaction prices fell 0.61% month over month in October, slightly more than in September. More notably, housing and A-share market capitalization both contracted during 2026, weakening the stock market’s buffer against housing-wealth losses. Morgan Stanley views this as a headwind for Chinese demand for European luxury goods, but its industry view remains In-Line.
Morgan Stanley believes Great Wall Motor’s sales and earnings may have passed their lows, but weak momentum in its core brands, a limited contribution from premiumization, and competitive and investment pressures on export growth have led the bank to sharply cut its profit forecasts for the next three years. It maintains different ratings for the Hong Kong-listed and A-share stocks.
In the week ended 30 October, US total prescriptions grew 5.2% year over year, but weakened week over week. Morgan Stanley is also tracking new-drug sales targets and prescription ramps: payment coverage, net-price assumptions and hospital-channel data all affect comparisons between forecasts and actual prescriptions.
Morgan Stanley believes that changes to SNAP and Medicaid cuts are the main channel through which elections affect consumption. Hispanic consumers’ beer spending continues to lag the overall market, while spirits companies show divergent trends; whether policy relief reaches companies will also depend on their customer bases and the share of their business in the U.S.
The US Treasury plans to switch to quarterly issuance of new 7-year notes, with two reopenings, starting in March 2027. Morgan Stanley estimates that the TY futures delivery basket will ultimately shrink from 12 securities to 8, but that the CTD switch threshold will move only 10 bp. The bank considers the recent relative outperformance of original-issue 10-year notes excessive; it also recommends exiting a May 45s/USZ 6s basis trade.
Morgan Stanley believes the index pullback has entered its later stages, with average stock performance and earnings revisions improving; its year-end S&P 500 base-case target is 8000 points. Broader earnings growth and cyclical-stock performance are supportive, while sentiment confirmation, financial conditions and liquidity are constraints.
The Vector advertising platform grew 40% sequentially in the third quarter, above management’s 20% guidance. Morgan Stanley believes advertising growth and margin expansion support upside potential as a standalone company; a potential acquisition is an additional option, but no deal has been determined and synergies remain unclear.
AT&S reported C3Q revenue grew 24% quarter over quarter, while the EBIT margin of Microelectronics (ABF substrates) rose to 30.5%. Morgan Stanley believes customer commitments support the Kulim expansion and also provide a positive signal for ABF peers; demand, alternative technologies and the ramp-up of new capacity remain industry constraints.
Morgan Stanley said Vir Biotechnology’s key HDV trials remain on track, VIR-5500 has achieved proof of concept and is planned to enter Phase III in 2027; however, the VIR-5818 data release has been delayed. The company expects its existing cash and payments from its Gilead collaboration to fund operations through the second half of 2028.
Third-quarter revenue grew 39% year over year, net retention rose to 122%, and fourth-quarter guidance came in above consensus; Morgan Stanley raised its revenue forecasts and is positive on Workers and security, while declining gross margin, compute investment and the sales handoff remain constraints.
Morgan Stanley believes ASML’s recent decline implies a sharp slowdown in AI-related wafer-fab investment, but no signs of a slowdown have emerged in DRAM or logic-chip capacity expansion. The firm maintains its Overweight rating and 1,700 euro price target, while acknowledging that DRAM expansion could flatten and capacity concerns could weigh on equipment expectations.
Zoryve third-quarter net product revenue of $144 million met expectations; after the full-year guidance increase, fourth-quarter growth is still expected to rely primarily on volume, while commercial investment and R&D spending push out the timing of operating leverage improvement.
As of the second quarter of 2026, highly AI-exposed sectors accounted for most of the increase in U.S. output per person measured by Morgan Stanley; gains were driven mainly by faster output growth, while weaker employment in some sectors indicates that labor substitution is beginning to emerge.
Navitas’ third-quarter revenue and fourth-quarter guidance both beat expectations, while orders and backlog support growth in 2027; however, material contributions from 800V designs are still further out. Claros-related expenses and dilution first weigh on earnings expectations, so Morgan Stanley raises its price target only slightly and maintains its Underweight rating.
A recovery in earnings-revision breadth and improvement in median-stock EPS support a broader spread of earnings growth. Morgan Stanley maintains its 8000-point year-end baseline for the S&P 500, but sentiment still needs confirmation, the equity risk premium is low, and liquidity and policy risks also limit the upside outlook.
Morgan Stanley expects AI chips to account for about one-third of the global semiconductor market in 2027; however, the growth rate of cloud providers’ capex, returns on AI investment, and advanced packaging capacity will determine whether demand can translate into supply-chain revenue.
Morgan Stanley combines quantitative scores and fundamental ratings to screen U.S. and European stocks reporting soon; the strategy has risen in Europe and fallen in the U.S. since 2026.
SpaceX signed a multi-year equipment agreement with Qualcomm and plans to deploy tens of thousands of macro sites starting in 2027. Morgan Stanley says this lends credibility to its plans to build its own ground network, but spectrum, capital investment and site selection will still determine the competitive and leasing impact.
Morgan Stanley believes the fire at Panasonic’s Hsinchu plant could accelerate its shift in capacity toward high-end CCL for AI and send some customer orders to competitors; the plant accounts for a small share of Panasonic Group’s overall capacity.